The pharmaceutical industry faces big challenges in drug discovery today – rising costs, high failure rates, and increasingly complex target diseases.

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Insilico Medicine, the biotech company with twin headquarters in Boston and Hong Kong, said it’s the first time an AI-created ...

Exclusive content, detailed data sets, and best-in-class trade insights to rewrite your portfolio for tomorrow. Founded in 2008, Gubra is a highly specialized preclinical CRO and biotech company ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion ...

A lab-designed molecule developed and extensively studied could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

Awareness Month, which seeks to raise recognition and push for research of this rare genomic imprinting disorder. PWS is ...

A new way of thinking about Alzheimer's disease has yielded a discovery that could be the key to stopping the cognitive decline seen in Alzheimer's and other neurodegenerative diseases, including ALS ...

Artificial intelligence (AI) and machine learning (ML) are ushering in a new era in drug discovery. The AlphaFold2 system developed by Google’s Deepmind was able to predict the 3D structures of ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

models intended to support drug discovery. The TxGemma models are – as the name suggests – an offshoot of Google's Gemma family of open-source, generative AI (GenAI) models that are ...